ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Wednesday, May 23, 2018

Submitted by

Mark Ferguson

Source

Source Name: The New England Journal of Medicine

Source URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1716078

Author(s)

Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, Valsamo Anagnostou, Tricia R. Cottrell,Matthew D. Hellmann, Marianna Zahurak, Stephen C. Yang, David R. Jones, Stephen Broderick, Richard J. Battafarano, Moises J. Velez, Natasha Rekhtman, Zachary Olah, Jarushka Naidoo, Kristen A. Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, Justina X. Caushi, Hok Yee Chan, John-William Sidhom, Robert B. Scharpf, James White, Edward Gabrielson, Hao Wang,Gary L. Rosner, Valerie Rusch, Jedd D. Wolchok, Taha Merghoub, Janis M. Taube, Victor E. Velculescu, Suzanne L. Topalian, Julie R. Brahmer, Drew M. Pardoll

This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to tumor mutational burden.